MetaCap

Accuray (ARAY) vs IceCure Medical (ICCM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Accuray is the larger company by market cap ($6.2 million vs $4.5 million), about 1.4 times the size, while IceCure Medical is growing revenue faster (+2.7% vs -12.3%). Accuray converts more of its revenue into profit, with a net margin of -12.2% versus -445.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARAY+718.86%ICCM-30.38%
+1481%+675%-130%
Oct 7, 20261 yearNov 20, 2026
ARAY+803.35%ICCM-27.22%
+1178%+533%-111%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARAY versus ICCM key metrics
MetricARAYICCM
Share price$2.08$0.8006
Market cap$6.22M$4.45M
1-day change-2.12%-19.71%
YTD return+153.05%—
1-year return+97.62%—
5-year return-59.47%—
EPS (TTM)$-5.60$-6.84
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$401.95M$3.38M
Revenue growth (YoY)-12.34%+2.67%
Net income (latest FY)$-49.19M$-15.06M
Gross margin27.73%36.28%
Operating margin-6.58%-446.70%
Net margin-12.24%-445.61%
52-week high$45.20$22.20
52-week low$2.05$0.65
Distance from 52-week high-95.41%-96.39%
Analyst consensusnonenone
Avg. price target upside—+2731.63%
Average volume201.35K186.02K
Shares outstanding3.00M5.56M
Employees80967
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Accuray is more profitable, keeping -12.2 cents of every revenue dollar as net income versus -445.6 cents for IceCure Medical.
  • IceCure Medical grew revenue faster in its latest fiscal year (+2.67% vs -12.34%).

About Accuray

ARAY stock →

Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.

Health Care · Medical/Dental Instruments · 809 employees

About IceCure Medical

ICCM stock →

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.

Health Care · Medical/Dental Instruments · 67 employees

ARAY vs ICCM FAQ

Which is bigger, Accuray or IceCure Medical?

Accuray (ARAY) is larger, with a market capitalization of $6.22M compared with $4.45M for IceCure Medical (ICCM).

Are Accuray and IceCure Medical in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons